Tumor-targeted and activated bioconjugates for improved camptothecin delivery

Area of Science:

• Drug delivery systems
• Cancer therapeutics
• Bioconjugation chemistry

Background:

• Earlier work established camptothecin (CPT) bioconjugates for tumor targeting.
• Cancer cells often overexpress the folic acid receptor, a target for drug delivery.

Purpose of the Study:

• To modulate the rate and site of CPT release from bioconjugates.
• To evaluate the efficacy of novel folate-targeted CPT delivery systems in a preclinical cancer model.

Main Methods:

• Utilized sterically hindered amino acids and cysteine proteinase-sensitive peptides to control CPT release kinetics.
• Employed polyethylene glycol as a scaffold linking CPT and folic acid.
• Assessed hydrolytic stability, enzyme-mediated cleavage, cytotoxicity, and targeting potential in vitro.
• Investigated conjugate efficacy in a syngeneic rat breast cancer model.
• Performed molecular modeling to correlate steric hindrance with hydrolysis half-life.

Main Results:

• Linkers successfully modulated CPT release rates (1–100 hours) and targeted the tumor microenvironment.
• A non-linear relationship was observed between steric hindrance and in vitro CPT release.
• Preliminary in vivo studies showed promising anti-tumor efficacy and reduced toxicity for programmed bioconjugates.

Conclusions:

• Programmed bioconjugates offer enhanced control over drug release kinetics and site-specificity.
• These advanced delivery systems demonstrate potential for improved anti-tumor efficacy and reduced systemic toxicity.